We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protalix BioTherapeutics Inc | AMEX:PLX | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.05 | -4.17% | 1.15 | 1.21 | 1.12 | 1.20 | 384,090 | 21:56:22 |
| | | | BY ORDER OF THE BOARD OF DIRECTORS | |
| | | |
|
|
|
Carmiel, Israel October 17, 2018 |
| |
Yossi Maimon
Vice President and Chief Financial Officer and Corporate Secretary |
|
Name and Address of Beneficial Owner
|
| |
Amount and
Nature of Beneficial Ownership |
| |
Percentage of
Class (%) |
| ||||||
Board of Directors and Executive Officers | | | | | | | | | | | | | |
Shlomo Yanai
(1)
|
| | | | 150,000 | | | | | | * | | |
Moshe Manor
(2)
|
| | | | 950,000 | | | | | | * | | |
Amos Bar Shalev
|
| | | | 1,680 | | | | | | * | | |
Zeev Bronfeld
(3)
|
| | | | 2,162,481 | | | | | | 1.5 | | |
Aharon Schwartz, Ph.D.
|
| | | | — | | | | | | — | | |
David Granot
|
| | | | — | | | | | | — | | |
Einat Brill Almon, Ph.D.
(4)
|
| | | | 533,750 | | | | | | * | | |
Yossi Maimon
(5)
|
| | | | 543,750 | | | | | | * | | |
Yaron Naos
(6)
|
| | | | 408,313 | | | | | | * | | |
Yoseph Shaaltiel, Ph.D.
(7)
|
| | | | 1,231,541 | | | | | | * | | |
All executive officers and directors as a group (10 persons)
(8)
|
| | | | 5,981,515 | | | | | | 4.0 | | |
5% Holders | | | | | | | | | | | | | |
Citigroup Global Markets Inc.
(9)
|
| | | | 9,390,588 | | | | | | 6.0 | | |
Highbridge Capital Management LLC
(10)
|
| | | | 16,459,608 | | | | | | 9.99 | | |
UBS O’Connor LLC
(11)
|
| | | | 9,411,764 | | | | | | 6.0 | | |
1 Year Protalix BioTherapeutics Chart |
1 Month Protalix BioTherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions